THERAPEUTIC DRUG MONITORING
Therapeutic drug monitoring is used to optimise drug regimens for the individual patient by increasing efficacy and avoiding drug-related toxicity. Prospective surveys suggest 20% patients in clinic have sub-therapeutic plasma concentrations of PIs and NNRTIs, while the inter-individual variability in plasma concentrations is immense (≥100-fold difference) despite standard dosing.
To review Liverpool HIV Pharmacology Group drug interactions web-site: LHPG
|
 |
Therapeutic drug monitoring is sponsored by the following pharmaceutical companies for the drugs / patient categories listed. Please contact your pharmaceutical company representative for full details. The pharmaceutical company will be invoiced directly for the cost of the analysis.
| Roche Products Ltd: |
Saquinavir and Nelfinavir |
| Merck Sharpe & Dohme: |
Indinavir in cases of suspected toxicity |
| Abbott Laboratories: |
Lopinavir for adult patients receiving Amprenavir and/or an NNRTI and all pregnant and paediatric patients* |
*Partial sponsorship - contact Abbott or Delphic for details
|
|
|
|
|
Delphic has developed a matrix of evidence for the clinical utility of therapeutic drug monitoring for HIV antiretroviral drugs (PIs and NNRTIs).
Please click here to review the site and register to access a commentary on current research and to receive email alerts advising new research affecting the balance of evidence. |
|
